Equity Overview
Price & Market Data
Price: $3.35
Daily Change: -$0.09 / 2.69%
Range: $2.99 - $3.52
Market Cap: $59,474,848
Volume: 357,988
Performance Metrics
1 Week: 5.20%
1 Month: 51.54%
3 Months: 46.38%
6 Months: 184.3%
1 Year: 3.61%
YTD: 56.36%
Details
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.